Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Garland James

Physician Assistant Silver Spring, MD Physician Assistant

NPI 1255968434 CMS profile 10534824

10313 Georgia Ave Ste 309, Silver Spring, MD 20902

Open in the dashboard

General payments

$85,579

789 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Garland James of Silver Spring, MD is reported in the CMS Open Payments database as having received $85,579 across 789 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $29,685 251
2024 General $28,361 173
2023 General $12,368 114
2022 General $8,459 105
2021 General $6,706 146

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Garland James
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Garland James were reported at $29,685. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Garland James Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $6,706 $132 $37–$438 $132
2022 $8,459 $155 $48–$522 $149
2023 $12,368 $167 $52–$557 $160
2024 $28,361 $178 $55–$600 $164
2025 $29,685 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. LEO Pharma Inc. $46,851 110 payments
  2. Lilly USA, LLC $9,427 52 payments
  3. UCB, Inc. $5,474 28 payments
  4. Eli Lilly and Company $5,422 11 payments
  5. AbbVie, Inc. $3,533 150 payments
  6. Regeneron Healthcare Solutions, Inc. $2,288 37 payments
  7. Dermavant Sciences, Inc. $2,156 31 payments
  8. Janssen Biotech, Inc. $1,357 51 payments
  9. E.R. Squibb & Sons, L.L.C. $1,340 31 payments
  10. Genzyme Corporation $1,259 33 payments
  11. Other $6,470 255 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $28,097 39 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $27,866 15 payments
  3. Food and Beverage $19,791 687 payments
  4. Travel and Lodging $8,865 34 payments
  5. Education $961 14 payments
Products named General payments · program years 2021–2025
  1. ADBRY $38,977 92 payments
  2. ANZUPGO $11,271 20 payments
  3. Bimzelx $5,397 25 payments
  4. EBGLYSS $3,318 12 payments
  5. OLUMIANT $2,836 8 payments
  6. VTAMA $2,205 35 payments
  7. DUPIXENT $1,689 22 payments
  8. SKYRIZI $1,635 56 payments
  9. TREMFYA $1,530 53 payments
  10. RINVOQ $1,379 55 payments
  11. Other $10,613 425 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

568

Median for Physician Assistant: 241

Drug cost

$9,869

Median for Physician Assistant: $4,110

Branded share of claims

0%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clobetasol Propionate Generic 32 $1,661
Betamethasone Dipropionate Generic 32 $1,441
Doxycycline Hyclate Generic 56 $1,391
Fluocinonide Generic 43 $1,357
Ketoconazole Generic 79 $1,114
Triamcinolone Acetonide Generic 55 $615
Clotrimazole Generic 23 $506
Clindamycin Phosphate Generic 13 $483
Minoxidil Generic 90 $411
Mupirocin Generic 33 $285

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$21,464

Medicare's payments for the services billed

Medicare patients

87

Average age 73

Services billed

575

49 women, 38 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Diabetes 39%
Ischemic heart disease 39%
Chronic kidney disease 36%
Heart failure 25%
Osteoporosis 21%
Cancer 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ADBRY
  • LEO Pharma Inc. $17,884
$17,884 — —
Bimzelx
  • UCB, Inc. $4,977
$4,977 — —
VTAMA
  • Dermavant Sciences, Inc. $1,728
$1,728 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $1,479
  • GENZYME CORPORATION $179
$1,658 — —
SKYRIZI
  • AbbVie, Inc. $312
$312 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

789 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record